Schizophrenia Clinical Trials in Atlanta, Georgia

21 studies are recruiting for schizophrenia in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Atlanta Center for Medical Research, Atlanta, Georgia

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

2. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   CenExel, Atlanta, Georgia

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

3. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Atlanta Center for Medical Research, Atlanta, Georgia

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

4. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Atlanta Center for Medical Research, Atlanta, Georgia

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

   A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Atlanta Center for Medical Research, Atlanta, Georgia

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07061288 on ClinicalTrials.gov

6. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Atlanta, Georgia

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

7. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   CenExeli Research LLC, Atlanta, Georgia

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

8. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Atlanta Center for Medical Research, Atlanta, Georgia

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

9. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

   The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Synexus Clinical Research US Inc, Atlanta, Georgia

   Locations

   8 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07615426 on ClinicalTrials.gov

10. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory University., Atlanta, Georgia

    Locations

    55 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

11. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

    This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

    Stage

    Phase 1

    Ages

    10 to 17

    Site

    BioXcel Clinical Research Site, Atlanta, Georgia

    Locations

    5 in total

    Run by

    BioXcel Therapeutics Inc

    See if you can join NCT05025605 on ClinicalTrials.gov

12. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Synexus Clinical Research US Inc - Atlanta, Atlanta, Georgia

    Locations

    73 in total

    Run by

    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

13. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Atlanta, Georgia

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

14. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Atlanta, Georgia

    Locations

    20 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

15. Anti-Inflammatory Challenge in Schizophrenia

    This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain circuits. The primary goal of this study is to determine: * Ventral St…

    Stage

    Phase 4

    Ages

    18 to 55

    Site

    Grady Memorial Hospital, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT05823532 on ClinicalTrials.gov

16. NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Atlanta, Georgia

    Locations

    15 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105098 on ClinicalTrials.gov

17. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Atlanta, Georgia

    Locations

    21 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

18. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Vanda Investigational Site, Atlanta, Georgia

    Locations

    22 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov

19. Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

    The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

    Stage

    Phase 3

    Ages

    13 to 17

    Site

    Atlanta Center for Medical Research, Atlanta, Georgia

    Locations

    57 in total

    Run by

    Gedeon Richter Plc.

    See if you can join NCT03817502 on ClinicalTrials.gov

20. Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

    Stage

    Phase 4

    Ages

    12 to 17

    Site

    Vanda Investigational Site, Atlanta, Georgia

    Locations

    9 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT05648591 on ClinicalTrials.gov

21. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Atlanta, Georgia

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov